Sinopharm Group China Bio announced the latest progress in the treatment of new crown pneumonia

On the 13th, Sinopharm Group China Bio announced the latest progress in the treatment of new crown pneumonia: Sinopharm China Bio has completed the collection of plasma from some recoverers and the preparation of New Crown Virus plasma-free products and special immunoglobulins. After rigorous blood bio safety testing, virus inactivation, and antiviral activity.

testing, special immune plasma has been successfully prepared for clinical treatment and put into clinical treatment of critically ill patients.

Relevant experts said that during the SARS outbreak, there were cases where SARS patients recovered plasma for patients with severe SARS to achieve cure. At present, under the premise of lack of vaccines and specific treatment drugs, the use of this special-free plasma product to treat new coronary pneumonia is the most effective method, which can significantly reduce the mortality of critically ill patients.

Starting from January 20, after a series of preparations and coordination, China Biological has set up a special team to mobilize relevant equipment and raw materials, and implemented plasma collection for patients with new crown pneumonia in Wuhan. On February 8th, under the guidance of the “New Corona virus Infected Pneumonia Diagnosis and Treatment Plan (Trial Fifth Edition)”, the first phase of the new crown-free plasma treatment for 3 critically ill patients was carried out in the First People’s Hospital of Jiangxia District, Wuhan City. There are currently more than 10 critically ill patients treated with follow-up hospitals. Clinically, after 12 to 24 hours of treatment, the main inflammatory indicators in the laboratory decreased significantly, the proportion of lymphocytes increased, key indicators such as blood oxygen saturation and viral load improved, and clinical signs and symptoms improved significantly.

Experts in the industry point out that from the perspective of clinical pathology, most patients with new crown pneumonia will have specific antibodies against the new crown virus in their bodies after treatment and rehabilitation, which can kill and clear the virus.

According to China Biological, this new crown free plasma product is prepared by the donors and containing high-cost new crown virus specific antibodies. The virus is inactivated, and it is prepared after detection of new crown virus neutralizing antibodies and multiple pathogenic microorganisms. It can be used for the treatment of critically ill patients with new coronary pneumonia. To this end, China Biological and Wuhan Blood Center issued a proposal to urge friends of Newcomer pneumonia patients to donate blood and donate blood to help other patients who are still in crisis.

The relevant person in charge of China Biological R & D said that the collection, preparation and serial detection of New Corona virus-free plasma has good safety, mature preparation technology and short time required. At present, the “2019-nCoV infection recovery period patient-specific plasma and specific immunoglobulin preparation” project undertaken by China Biological has been awarded the national key R & D plan “public safety risk prevention and control and emergency technology equipment” key project organized by the Ministry of Science and Technology. The project has received strong support from the Hubei Provincial Department of Science and Technology and the Health and Medical Commission.

After the epidemic, China’s biology attaches great importance to it. On January 20, an emergency response plan for epidemic prevention and control was immediately launched, a working leadership group was established, and a new scientific research team for new corona virus was formed. Yang Xiaoming, Chief Scientist of the 863 Program Vaccine Project and Chairman of China Biological, served as Chief Commander, focusing on the development of new crown virus-related diagnostic reagents, new crown virus-free plasma products, new crown virus immunoglobulin, new crown virus inactivated vaccine, new crown virus recombinant genetic engineering Scientific research on vaccines, monoclonal antibodies against new crown virus, etc. Among them, Zhongsheng Shanghai Genuo took the lead in developing the New Crown Virus Nucleic Acid Molecular Detection Kit and obtained the first batch of registration certificates issued by the State Drug Administration; for the epidemic-stricken areas in Wuhan, Hubei, a front-line command headquarters was established to combat the epidemic, and China Bio Dr. Duan Kai, General Manager of Wuhan Institute of Biological Products, is responsible for mobilizing and coordinating front-line resources. With the efforts and active coordination of the Hubei Provincial Department of Science and Technology, we are racing against time to promote the new crown-free plasma products, new crown virus inactivated vaccines, monoclonal antibodies and other projects. Scientific research.

Chinese biology attaches great importance to the research and development of new corona viruses, and it has urgently arranged 400 million yuan in research and development funds in advance, using various technological platforms of Chinese biology, and working with the National Center for Disease Control, Wuhan Institute of Virology, Chinese Academy of Sciences, and Wuhan hospitals. The relevant units have cooperated closely and received strong support from the relevant state departments and various departments in Hubei Province and Wuhan. China Bio said that in the next step, it will fully promote the research and development of preventive and therapeutic products to ensure that the work is accurate, orderly and efficient.